InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
-14.4%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by HUNT RONALD, Director. Officer active across 3 companies, notably Rallybio Corp. In total, 18 disclosures have been recorded. Split: 4 buys · 0 sell. Total volume traded: €15.8m. History available since 11 January 2021. The latest transaction was filed on 8 March 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
182,453 sharesOrdinary SharesSEC:0000950170-24-095094:0
424 shares0Common StockSEC:0000950170-24-029446:0
1,072 shares0Common StockSEC:0000950170-24-000960:0
5,000 shares0Common StockSEC:0001209191-23-056796:0
1,372,000 sharesCommon StockSEC:0001209191-23-053737:0
Ideal exit: 21 Jul 2024 (T+270)
5,479 sharesOrdinary SharesSEC:0001209191-23-050912:0
3,035 shares0Common StockSEC:0001209191-23-051149:0
18,656 shares0Common StockSEC:0001209191-23-041671:0
2,796 sharesOrdinary SharesSEC:0001209191-23-040405:0
18,285 shares0Common StockSEC:0001209191-23-022802:0
2,041 shares0Ordinary SharesSEC:0001209191-23-022424:0
10,000 shares@ US$1,000.0058.4% of flow8.000% Series A Redeemable Preferred StockSEC:0000899243-23-009741:0
Ideal exit: 18 Dec 2023 (T+270)
1,197 sharesOrdinary SharesSEC:0001209191-23-001286:0
36,798 sharesOrdinary SharesSEC:0001209191-22-039314:0
235,294 shares@ US$17.0050.0% of flowCommon StockSEC:0000899243-21-032747:0
Ideal exit: 8 Oct 2021 (T+270)
235,294 shares@ US$17.0020.8% of flowCommon StockSEC:0000899243-21-032747
Ideal exit: 8 Oct 2021 (T+270)
1,993,911 sharesCommon StockSEC:0000899243-21-031634:0
1,993,911 sharesCommon StockSEC:0000899243-21-031634
18 of 18 declarations
About HUNT RONALD
Ronald Hunt is a Board Member at Rallybio Corp, Harpoon Therapeutics, Inc., and Iterum Therapeutics plc. He is involved in governance and strategic decision-making for each of these companies. With expertise in the biopharmaceutical sector, Ronald contributes to innovation and sustainability within the organizations.
